Uploaded March 2025 | Updated September 2026, 1 week ago
GLP-1 receptor agonists (like Ozempic, Mounjaro, and others) are making waves in the diabetes world. But how do they interact with diabetes tech like CGMs, insulin pumps, and hybrid closed-loop systems? In this video, I dive deep into the advantages and disadvantages of GLP-1s—covering everything from insulin dose reductions to unexpected changes.
I also bring in real-world experiences from my friends Melissa Holloway and Tim Street who are both using GLP-1s with diabetes tech to manage their type 1 diabetes. If you’re curious about how GLP-1s fit into a tech-driven diabetes management plan, this is the video for you!
PLEASE NOTE THIS IS NOT MEDICAL ADVICE
Let me know what you think about GLP-1s. What are you most looking forward to?
If you would like to reach out email me at nerdabetic@gmail.com
*******************************************
My email address: nerdabetic@gmail.com
My Instagram: instagram.com/nerdabetic
My X: https://x.com/nerdabetic
*******************************************
GLP-1 receptor agonists (like Ozempic, Mounjaro, and others) are making waves in the diabetes world. But how do they interact with diabetes tech like CGMs, insulin pumps, and hybrid closed-loop systems? In this video, I dive deep into the advantages and disadvantages of GLP-1s—covering everything from insulin dose reductions to unexpected changes.
I also bring in real-world experiences from my friends Melissa Holloway and Tim Street who are both using GLP-1s with diabetes tech to manage their type 1 diabetes. If you’re curious about how GLP-1s fit into a tech-driven diabetes management plan, this is the video for you!
PLEASE NOTE THIS IS NOT MEDICAL ADVICE
Let me know what you think about GLP-1s. What are you most looking forward to?
If you would like to reach out email me at nerdabetic@gmail.com
*******************************************
My email address: nerdabetic@gmail.com
My Instagram: instagram.com/nerdabetic
My X: https://x.com/nerdabetic
*******************************************










